{"id":"NCT02268396","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD","officialTitle":"An Open-Label, Multi-Center, Dose Indicator Study of Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) in Adult Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2015-01","completion":"2015-05","firstPosted":"2014-10-20","resultsPosted":"2016-12-23","lastUpdate":"2016-12-23"},"enrollment":138,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler","otherNames":["GFF MDI, PT003"]}],"arms":[{"label":"Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multi-center study to evaluate the accuracy, reliability and functionality of the Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) dose indicator in adult subjects with moderate to very severe COPD over a 4-week Treatment Period.","primaryOutcome":{"measure":"Dose Indicator Actuation Consistency: Percentage of Devices in Agreement Between CRF-Based Dose Indicator Actuation Count","timeFrame":"Over the life of the canister/120 puffs - up to 4 weeks","effectByArm":[{"arm":"GFF MDI (PT003)","deltaMin":96.4,"sd":18.9}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["30335559"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":138},"commonTop":["COPD"]}}